{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T03:51:04Z","timestamp":1774842664802,"version":"3.50.1"},"reference-count":37,"publisher":"American Society of Hematology","issue":"9","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2005,5,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Mantle-cell lymphoma (MCL) is a unique subtype of B-cell non-Hodgkin lymphoma (NHL) that behaves aggressively and remains incurable. In order to understand the pathogenesis of MCL and design new therapies, it is important to accurately analyze molecular changes in pathways dysregulated in MCL. We used antibody microarrays to compare patterns of protein expression between CD19+ purified B lymphocytes from normal tonsil and 7 cases of histologically confirmed MCL. Protein overexpression was defined as a higher than 1.3-fold or 2-fold increase in at least 67% of tumor samples compared with normal B-cell control. Of the polypeptides, 77 were overexpressed using the higher than 1.3-fold cutoff, and 13 were overexpressed using the 2-fold cutoff. These included cell cycle regulators (regulator of chromosome condensation 1 [RCC1], murine double minute 2 [MDM2]), a kinase (citron Rho-interacting kinase [CRIK]), chaperone proteins (heat shock 90-kDa protein [Hsp90], Hsp10), and phosphatase regulators (A-kinase anchor protein 1 [AKAP149], protein phosphatase 5 [PP5], and inhibitor 2). The elevated expression of some of these polypeptides was confirmed by immunoblotting and immunohistochemistry, whereas elevated expression of others could not be confirmed, illustrating the importance of confirmatory studies. This study describes a novel technique that identifies proteins dysregulated in MCL.<\/jats:p>","DOI":"10.1182\/blood-2004-10-3999","type":"journal-article","created":{"date-parts":[[2005,1,14]],"date-time":"2005-01-14T01:29:44Z","timestamp":1105666184000},"page":"3722-3730","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":112,"title":["Proteomic analysis of mantle-cell lymphoma by protein microarray"],"prefix":"10.1182","volume":"105","author":[{"given":"Irene M.","family":"Ghobrial","sequence":"first","affiliation":[{"name":"From the Division of Hematology, Department of Internal Medicine; the Proteomic Core, Biochemistry and Molecular Biology; the Department of Oncology; the Genomics Core, Molecular Biology; and Experimental Pathology, Department of Pathology, Mayo Clinic, Rochester, MN; and the Department of Pathology, VA Pittsburgh Healthcare System, University of Pittsburgh, Pittsburgh, PA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel J.","family":"McCormick","sequence":"additional","affiliation":[{"name":"From the Division of Hematology, Department of Internal Medicine; the Proteomic Core, Biochemistry and Molecular Biology; the Department of Oncology; the Genomics Core, Molecular Biology; and Experimental Pathology, Department of Pathology, Mayo Clinic, Rochester, MN; and the Department of Pathology, VA Pittsburgh Healthcare System, University of Pittsburgh, Pittsburgh, PA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott H.","family":"Kaufmann","sequence":"additional","affiliation":[{"name":"From the Division of Hematology, Department of Internal Medicine; the Proteomic Core, Biochemistry and Molecular Biology; the Department of Oncology; the Genomics Core, Molecular Biology; and Experimental Pathology, Department of Pathology, Mayo Clinic, Rochester, MN; and the Department of Pathology, VA Pittsburgh Healthcare System, University of Pittsburgh, Pittsburgh, PA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexey A.","family":"Leontovich","sequence":"additional","affiliation":[{"name":"From the Division of Hematology, Department of Internal Medicine; the Proteomic Core, Biochemistry and Molecular Biology; the Department of Oncology; the Genomics Core, Molecular Biology; and Experimental Pathology, Department of Pathology, Mayo Clinic, Rochester, MN; and the Department of Pathology, VA Pittsburgh Healthcare System, University of Pittsburgh, Pittsburgh, PA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David A.","family":"Loegering","sequence":"additional","affiliation":[{"name":"From the Division of Hematology, Department of Internal Medicine; the Proteomic Core, Biochemistry and Molecular Biology; the Department of Oncology; the Genomics Core, Molecular Biology; and Experimental Pathology, Department of Pathology, Mayo Clinic, Rochester, MN; and the Department of Pathology, VA Pittsburgh Healthcare System, University of Pittsburgh, Pittsburgh, PA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nga T.","family":"Dai","sequence":"additional","affiliation":[{"name":"From the Division of Hematology, Department of Internal Medicine; the Proteomic Core, Biochemistry and Molecular Biology; the Department of Oncology; the Genomics Core, Molecular Biology; and Experimental Pathology, Department of Pathology, Mayo Clinic, Rochester, MN; and the Department of Pathology, VA Pittsburgh Healthcare System, University of Pittsburgh, Pittsburgh, PA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kelly L.","family":"Krajnik","sequence":"additional","affiliation":[{"name":"From the Division of Hematology, Department of Internal Medicine; the Proteomic Core, Biochemistry and Molecular Biology; the Department of Oncology; the Genomics Core, Molecular Biology; and Experimental Pathology, Department of Pathology, Mayo Clinic, Rochester, MN; and the Department of Pathology, VA Pittsburgh Healthcare System, University of Pittsburgh, Pittsburgh, PA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary J.","family":"Stenson","sequence":"additional","affiliation":[{"name":"From the Division of Hematology, Department of Internal Medicine; the Proteomic Core, Biochemistry and Molecular Biology; the Department of Oncology; the Genomics Core, Molecular Biology; and Experimental Pathology, Department of Pathology, Mayo Clinic, Rochester, MN; and the Department of Pathology, VA Pittsburgh Healthcare System, University of Pittsburgh, Pittsburgh, PA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mona F.","family":"Melhem","sequence":"additional","affiliation":[{"name":"From the Division of Hematology, Department of Internal Medicine; the Proteomic Core, Biochemistry and Molecular Biology; the Department of Oncology; the Genomics Core, Molecular Biology; and Experimental Pathology, Department of Pathology, Mayo Clinic, Rochester, MN; and the Department of Pathology, VA Pittsburgh Healthcare System, University of Pittsburgh, Pittsburgh, PA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne J.","family":"Novak","sequence":"additional","affiliation":[{"name":"From the Division of Hematology, Department of Internal Medicine; the Proteomic Core, Biochemistry and Molecular Biology; the Department of Oncology; the Genomics Core, Molecular Biology; and Experimental Pathology, Department of Pathology, Mayo Clinic, Rochester, MN; and the Department of Pathology, VA Pittsburgh Healthcare System, University of Pittsburgh, Pittsburgh, PA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen M.","family":"Ansell","sequence":"additional","affiliation":[{"name":"From the Division of Hematology, Department of Internal Medicine; the Proteomic Core, Biochemistry and Molecular Biology; the Department of Oncology; the Genomics Core, Molecular Biology; and Experimental Pathology, Department of Pathology, Mayo Clinic, Rochester, MN; and the Department of Pathology, VA Pittsburgh Healthcare System, University of Pittsburgh, Pittsburgh, PA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas E.","family":"Witzig","sequence":"additional","affiliation":[{"name":"From the Division of Hematology, Department of Internal Medicine; the Proteomic Core, Biochemistry and Molecular Biology; the Department of Oncology; the Genomics Core, Molecular Biology; and Experimental Pathology, Department of Pathology, Mayo Clinic, Rochester, MN; and the Department of Pathology, VA Pittsburgh Healthcare System, University of Pittsburgh, Pittsburgh, PA."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"key":"2020021222420860500_REF1","doi-asserted-by":"crossref","unstructured":"Argatoff LH, Connors JM, Klasa RJ, Horsman DE, Gascoyne RD. Mantle cell lymphoma: a clinicopathologic study of 80 cases. Blood. 1997;89: 2067-2078.","DOI":"10.1182\/blood.V89.6.2067"},{"key":"2020021222420860500_REF2","doi-asserted-by":"crossref","unstructured":"Kurtin, PM. Mantle cell lymphoma. Adv Anat Pathol. 1998;5: 376-398.","DOI":"10.1097\/00125480-199811000-00011"},{"key":"2020021222420860500_REF3","doi-asserted-by":"crossref","unstructured":"Yatabe Y, Suzuki R, Matsuno Y, et al. Morphological spectrum of cyclin D1-positive mantle cell lymphoma: study of 168 cases. Pathol Int. 2001;51: 747-761.","DOI":"10.1046\/j.1440-1827.2001.01277.x"},{"key":"2020021222420860500_REF4","unstructured":"Katz RL Wojcik EM, el-Naggar AK, Ordonez NG, Johnston DA. Proliferation markers in non-Hodgkin's lymphoma: a comparative study between cytophotometric quantitation of Ki-67 and flow cytometric proliferation index on fine needle aspirates. Anal Quant Cytol Histol. 1993;15: 179-186."},{"key":"2020021222420860500_REF5","doi-asserted-by":"crossref","unstructured":"Weisenburger D, Vose JM, Greiner TC, et al. Mantle cell lymphoma: a clinicopathologic study of 68 cases from the Nebraska Lymphoma Study Group. Amer J Hematol. 2000;64: 190-196.","DOI":"10.1002\/1096-8652(200007)64:3<190::AID-AJH9>3.0.CO;2-B"},{"key":"2020021222420860500_REF6","doi-asserted-by":"crossref","unstructured":"Oinonen R, Franssila K, Teerenhovi L, Lappalainen K, Elonen E. Mantle cell lymphoma: clinical features, treatment and prognosis of 94 patients. Eur J Cancer. 1998;34: 329-336.","DOI":"10.1016\/S0959-8049(97)10056-9"},{"key":"2020021222420860500_REF7","doi-asserted-by":"crossref","unstructured":"Hiddemann W, Unterhalt M, Herrmann R, et al. Mantle-cell lymphomas have more widespread disease and a slower response to chemotherapy compared with follicle-center lymphomas: results of a prospective comparative analysis of the German Low-Grade Lymphoma Study Group. J Clin Oncol. 1998;16: 1922-1930.","DOI":"10.1200\/JCO.1998.16.5.1922"},{"key":"2020021222420860500_REF8","doi-asserted-by":"crossref","unstructured":"Bodrug SEW, Bath ML, Lindeman GJ, Harris AW, Adams JM. Cyclin D1 transgene impedes lymphocyte maturation and collaborates in lymphomagenesis with the myc gene. EMBO J. 1994;13: 2124-2130.","DOI":"10.1002\/j.1460-2075.1994.tb06488.x"},{"key":"2020021222420860500_REF9","doi-asserted-by":"crossref","unstructured":"Stilgenbauer S, Schaffner C, Winkler D, et al. The ATM gene in the pathogenesis of mantle-cell lymphoma. Ann Oncol. 2000;11(suppl 1): 127-130.","DOI":"10.1093\/annonc\/11.suppl_1.S127"},{"key":"2020021222420860500_REF10","unstructured":"Martinez NC, Algara P, Rodriguez A, et al. The molecular signature of mantle cell lymphoma reveals multiple signals favoring cell survival. Cancer Res. 2003;63: 8226-8232."},{"key":"2020021222420860500_REF11","doi-asserted-by":"crossref","unstructured":"Antonucci FC, Parolini C, Hamdan M, Astner H, Righetti PG. Two-dimensional molecular profiling of mantle cell lymphoma. Electrophoresis. 2003;24: 2376-2385.","DOI":"10.1002\/elps.200305457"},{"key":"2020021222420860500_REF12","doi-asserted-by":"crossref","unstructured":"Hamdan M, Righetti PG. Assessment of protein expression by means of 2-D gel electrophoresis with and without mass spectrometry. Mass Spectrom Rev. 2003;22: 272-284.","DOI":"10.1002\/mas.10056"},{"key":"2020021222420860500_REF13","doi-asserted-by":"crossref","unstructured":"Zhu H, Snyder M. Protein chip technology. Curr Opin Chem Biol. 2003;7: 55-63.","DOI":"10.1016\/S1367-5931(02)00005-4"},{"key":"2020021222420860500_REF14","unstructured":"Meeker T, Sellers W, Harvey R, et al. Cloning of the t(11;14)(q13;q32) translocation breakpoints from two human leukemia cell lines. Leukemia. 1991;5: 733-737."},{"key":"2020021222420860500_REF15","unstructured":"BD Biosciences. Antibody microarray analysis workbook. http:\/\/bioinfo2.clontech.com\/abinfo\/array-list-action.do. Accessed January 7, 2005."},{"key":"2020021222420860500_REF16","doi-asserted-by":"crossref","unstructured":"Svingen P, Karp JE, Krajewski S, et al. Evaluation of Apaf-1 and procaspases-2, -3, -7, -8, and -9 as potential prognostic markers in acute leukemia. Blood. 2000;96: 3922-3931.","DOI":"10.1182\/blood.V96.12.3922"},{"key":"2020021222420860500_REF17","doi-asserted-by":"crossref","unstructured":"Chen G, Gharib TG, Huang CC, et al. Discordant protein and mRNA expression in lung adenocarcinomas. Mol Cell Proteomics. 2002;1: 304-313.","DOI":"10.1074\/mcp.M200008-MCP200"},{"key":"2020021222420860500_REF18","doi-asserted-by":"crossref","unstructured":"Svingen PA, Loegering DA, Meng XW, et al. Components of the cell death machine and drug sensitivity of the NCI cell line panel. Clinical Cancer Res. 2004;10: 6807-6820.","DOI":"10.1158\/1078-0432.CCR-0778-02"},{"key":"2020021222420860500_REF19","doi-asserted-by":"crossref","unstructured":"Eischen C, Weber JD, Roussel MF, Sherr CJ, Cleveland JL. Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis. Genes Dev. 1999;13: 2658-2669.","DOI":"10.1101\/gad.13.20.2658"},{"key":"2020021222420860500_REF20","doi-asserted-by":"crossref","unstructured":"Alt J, Greiner TC, Cleveland JL, Eischen CM. Mdm2 haplo-insufficiency profoundly inhibits Myc-induced lymphomagenesis. EMBO J. 2003;22: 1442-1450.","DOI":"10.1093\/emboj\/cdg133"},{"key":"2020021222420860500_REF21","doi-asserted-by":"crossref","unstructured":"Watanabe T, Ichikawa A, Saito H, Hotta T. Overexpression of the MDM2 oncogene in leukemia and lymphoma. Leuk Lymphoma. 1996;21: 391-397.","DOI":"10.3109\/10428199609093436"},{"key":"2020021222420860500_REF22","doi-asserted-by":"crossref","unstructured":"Pagnano K, Vassallo J, Lorand-Metze I, Costa FF, Saad ST. p53, Mdm2, and c-Myc overexpression is associated with a poor prognosis in aggressive non-Hodgkin's lymphomas [erratum published in: Am J Hematol. 2001;67:279]. Am J Hematol. 2001;67: 84-92.","DOI":"10.1002\/ajh.1084"},{"key":"2020021222420860500_","doi-asserted-by":"crossref","unstructured":"Lindstrom M, Klangby U, Wiman KG. p14ARF homozygous deletion or MDM2 overexpression in Burkitt lymphoma lines carrying wild type p53. Oncogene. 2001;20: 2171-2177.","DOI":"10.1038\/sj.onc.1204303"},{"key":"2020021222420860500_REF24","doi-asserted-by":"crossref","unstructured":"Moller M, Nielsen O, Pedersen NT. Frequent alteration of MDM2 and p53 in the molecular progression of recurring non-Hodgkin's lymphoma. Histopathology. 2002;41: 322-330.","DOI":"10.1046\/j.1365-2559.2002.01506.x"},{"key":"2020021222420860500_REF25","unstructured":"Solenthaler M, Matutes E, Brito-Babapulle V, Morilla R, Catovsky D. p53 and mdm2 in mantle cell lymphoma in leukemic phase. Haematologica. 2002;87: 1141-1150."},{"key":"2020021222420860500_REF26","doi-asserted-by":"crossref","unstructured":"Bischoff F, Ponstingl H. Mitotic regulator protein RCC1 is complexed with a nuclear ras-related polypeptide. Proc Natl Acad Sci U S A. 1991;88: 10830-10834.","DOI":"10.1073\/pnas.88.23.10830"},{"key":"2020021222420860500_REF27","doi-asserted-by":"crossref","unstructured":"Bischoff F, Ponstingl H. Catalysis of guanine nucleotide exchange on Ran by the mitotic regulator RCC1. Nature. 1991;354: 80-82.","DOI":"10.1038\/354080a0"},{"key":"2020021222420860500_REF28","doi-asserted-by":"crossref","unstructured":"Dasso M, Nishitani H, Kornbluth S, Nishimoto T, Newport JW. RCC1, a regulator of mitosis, is essential for DNA replication. Mol Cell Biol. 1992;12: 3337-3345.","DOI":"10.1128\/MCB.12.8.3337"},{"key":"2020021222420860500_REF29","doi-asserted-by":"crossref","unstructured":"Ren M, Drivas G, D'Eustachio P, Rush MG. Ran\/TC4: a small nuclear GTP-binding protein that regulates DNA synthesis. J Cell Biol. 1993;120: 313-323.","DOI":"10.1083\/jcb.120.2.313"},{"key":"2020021222420860500_REF30","doi-asserted-by":"crossref","unstructured":"Berger A, Tang G, Alexander HR, Libutti SK. Endothelial monocyte-activating polypeptide II, a tumor-derived cytokine that plays an important role in inflammation, apoptosis, and angiogenesis. J Immunother. 2000;23: 519-527.","DOI":"10.1097\/00002371-200009000-00002"},{"key":"2020021222420860500_REF31","doi-asserted-by":"crossref","unstructured":"Murray J, Heng YM, Symonds P, et al. Endothelial monocyte-activating polypeptide-II (EMAP-II): a novel inducer of lymphocyte apoptosis. J Leukoc Biol. 2004;75: 772-776.","DOI":"10.1189\/jlb.1003487"},{"key":"2020021222420860500_REF32","doi-asserted-by":"crossref","unstructured":"Murray J, Symonds P, Ward W, et al. Colorectal cancer cells induce lymphocyte apoptosis by an endothelial monocyte-activating polypeptide-II-dependent mechanism. J Immunol. 2004;172: 274-281.","DOI":"10.4049\/jimmunol.172.1.274"},{"key":"2020021222420860500_REF33","doi-asserted-by":"crossref","unstructured":"Wera S, Hemmings BA. Serine\/threonine protein phosphatases. Biochem J. 1995;311(pt 1): 17-29.","DOI":"10.1042\/bj3110017"},{"key":"2020021222420860500_REF34","unstructured":"Xu W, Yuan X, Jung YJ, et al. The heat shock protein 90 inhibitor geldanamycin and the ErbB inhibitor ZD1839 promote rapid PP1 phosphatase-dependent inactivation of AKT in ErbB2 overexpressing breast cancer cells. Cancer Res. 2003;63: 7777-7784."},{"key":"2020021222420860500_REF35","doi-asserted-by":"crossref","unstructured":"Satinover D, Leach CA, Stukenberg PT, Brautigan DL. Activation of Aurora-A kinase by protein phosphatase inhibitor-2, a bifunctional signaling protein. Proc Natl Acad Sci U S A. 2004;101: 8625-8630.","DOI":"10.1073\/pnas.0402966101"},{"key":"2020021222420860500_REF36","doi-asserted-by":"crossref","unstructured":"Di Cunto F, Calautti E, Hsiao J, et al. Citron rho-interacting kinase, a novel tissue-specific ser\/thr kinase encompassing the Rho-Rac-binding protein Citron. J Biol Chem. 1998;273: 29706-29711.","DOI":"10.1074\/jbc.273.45.29706"},{"key":"2020021222420860500_REF37","doi-asserted-by":"crossref","unstructured":"Ridley A. Rho proteins and cancer. Breast Cancer Res Treat. 2004;84: 13-19.","DOI":"10.1023\/B:BREA.0000018423.47497.c6"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/105\/9\/3722\/1709629\/zh800905003722.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/105\/9\/3722\/1709629\/zh800905003722.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,13]],"date-time":"2020-02-13T03:42:20Z","timestamp":1581565340000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/105\/9\/3722\/21259\/Proteomic-analysis-of-mantlecell-lymphoma-by"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,5,1]]},"references-count":37,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2005,5,1]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2004-10-3999","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,5,1]]}}}